Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that new data from a post hoc analysis of circulating proteomic data from participants enrolled in its Launch-HTN and Advance-HTN trials will be featured in a late-breaking poster presentation at ENDO 2026, the Endocrine Society's annual meeting, taking place June 13-16, 2026 in Chicago, Illinois.